This site is intended for healthcare professionals

FDA approves Ultomiris for children and adolescents with paroxysmal nocturnal hemoglobinuria.- Alexion Pharmaceuticals

Read time: 1 mins
Last updated:8th Jun 2021
Published:9th Jun 2021
Alexion Pharmaceuticals, Inc. announced the FDA has approved the expanded use of Ultomiris (ravulizumab-cwvz) to include children (one month of age and older) and adolescents with paroxysmal nocturnal hemoglobinuria (PNH). Ultomiris, a long-acting C5 inhibitor that offers immediate, complete and sustained complement inhibition, is now the first and only FDA-approved medicine for children and adolescents with PNH.
Condition: Paroxysmal Nocturnal Haemoglobinuria
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest